Authors
David B Badesch, Victor F Tapson, Michael D McGoon, Bruce H Brundage, Lewis J Rubin, Fredrick M Wigley, Stuart Rich, Robyn J Barst, Pamela S Barrett, Kenneth M Kral, Maria M Jöbsis, James E Loyd, Srinivas Murali, Adaani Frost, Reda Girgis, Robert C Bourge, David D Ralph, C Gregory Elliott, Nicholas S Hill, David Langleben, Robert J Schilz, Vallerie V McLaughlin, Ivan M Robbins, Bertron M Groves, Shelley Shapiro, Thomas A Medsger Jr, Sean P Gaine, Evelyn Horn, James C Decker, Katharine Knobil
Publication date
2000/3/21
Journal
Annals of internal medicine
Volume
132
Issue
6
Pages
425-434
Publisher
American College of Physicians
Description
Background
Pulmonary hypertension is a progressive and often fatal complication of the scleroderma spectrum of disease for which no treatment has been proven effective in a randomized trial.
Objective
To determine the effect of epoprostenol on pulmonary hypertension secondary to the scleroderma spectrum of disease.
Design
Randomized, open-label, controlled trial.
Setting
17 pulmonary hypertension referral centers.
Patients
111 patients with moderate to severe pulmonary hypertension.
Intervention
Epoprostenol plus conventional therapy or conventional therapy alone.
Measurements
The primary outcome measure was exercise capacity. Other measures were cardiopulmonary hemodynamics, signs and …
Total citations
Scholar articles
DB Badesch, VF Tapson, MD McGoon, BH Brundage… - Annals of internal medicine, 2000